Skip to content

aTyr Pharma ATYR Free cash flow margin

Free cash flow margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
24.6%-2.9pp
Merck & Co. logo
Merck & Co.MRK
21.5%-5.2pp
United Therapeutics logo
United TherapeuticsUTHR
32.1%-5.6pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-187.2%-85.4pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
36.2%+18.4pp
Zymeworks logo
ZymeworksZYME
-94.8%+15.5pp

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%
EPS (diluted)-$0.11+35.3%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Calculated from aTyr Pharma’s reported figures.

Based on trailing twelve months.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's free cash flow margin?
aTyr Pharma (ATYR) reported free cash flow margin of -32,664.7% in Q4 2025.
How has aTyr Pharma's free cash flow margin changed year-over-year?
aTyr Pharma's free cash flow margin decreased by 11.0% year-over-year, from -29,440% to -32,664.7%.
What is the long-term trend for aTyr Pharma's free cash flow margin?
Over 3 years (2020 to 2025), aTyr Pharma's free cash flow margin has grown at a 503.9% compound annual growth rate (CAGR), from -148.3% to -32,664.7%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.